A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.

Trial Profile

A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Neuroendocrine tumours
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 13 Aug 2013 Planned end date changed from 1 Apr 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 12 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top